MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans
Strategies to enhance the induction of high magnitude T cell responses through vaccination are urgently needed. Major histocompatibility complex (MHC) class II–associated invariant chain (Ii) plays a critical role in antigen presentation, forming MHC class II peptide complexes for the generation of...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Outros Autores: | |
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
American Association for the Advancement of Science
2020
|
| _version_ | 1826300568610537472 |
|---|---|
| author | Esposito, I Cicconi, P D'Alise, AM Brown, A Esposito, M Swadling, L Holst, PJ Bassi, MR Stornaiuolo, M Mori, F Vassilev, V Li, W Donnison, T Gentile, C Turner, B von Delft, A Del Sorbo, M Barra, F Contino, AM Abbate, A Novellino, E Thomsen, AR Christensen, JP Lahm, A Grazioli, F Ammendola, V Siani, L Colloca, S Klenerman, P Nicosia, A Dorrell, L Folgori, A Capone, S Barnes, E |
| author2 | PEACHI Consortium |
| author_facet | PEACHI Consortium Esposito, I Cicconi, P D'Alise, AM Brown, A Esposito, M Swadling, L Holst, PJ Bassi, MR Stornaiuolo, M Mori, F Vassilev, V Li, W Donnison, T Gentile, C Turner, B von Delft, A Del Sorbo, M Barra, F Contino, AM Abbate, A Novellino, E Thomsen, AR Christensen, JP Lahm, A Grazioli, F Ammendola, V Siani, L Colloca, S Klenerman, P Nicosia, A Dorrell, L Folgori, A Capone, S Barnes, E |
| author_sort | Esposito, I |
| collection | OXFORD |
| description | Strategies to enhance the induction of high magnitude T cell responses through vaccination are urgently needed. Major histocompatibility complex (MHC) class II–associated invariant chain (Ii) plays a critical role in antigen presentation, forming MHC class II peptide complexes for the generation of CD4+ T cell responses. Preclinical studies evaluating the fusion of Ii to antigens encoded in vector delivery systems have shown that this strategy may enhance T cell immune responses to the encoded antigen. We now assess this strategy in humans, using chimpanzee adenovirus 3 and modified vaccinia Ankara vectors encoding human Ii fused to the nonstructural (NS) antigens of hepatitis C virus (HCV) in a heterologous prime/boost regimen. Vaccination was well tolerated and enhanced the peak magnitude, breadth, and proliferative capacity of anti-HCV T cell responses compared to non-Ii vaccines in humans. Very high frequencies of HCV-specific T cells were elicited in humans. Polyfunctional HCV-specific CD8+ and CD4+ responses were induced with up to 30% of CD3+CD8+ cells targeting single HCV epitopes; these were mostly effector memory cells with a high proportion expressing T cell activation and cytolytic markers. No volunteers developed anti-Ii T cell or antibody responses. Using a mouse model and in vitro experiments, we show that Ii fused to NS increases HCV immune responses through enhanced ubiquitination and proteasomal degradation. This strategy could be used to develop more potent HCV vaccines that may contribute to the HCV elimination targets and paves the way for developing class II Ii vaccines against cancer and other infections. |
| first_indexed | 2024-03-07T05:19:09Z |
| format | Journal article |
| id | oxford-uuid:de46addf-b6fd-41b8-a02d-ee2c74e52996 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:19:09Z |
| publishDate | 2020 |
| publisher | American Association for the Advancement of Science |
| record_format | dspace |
| spelling | oxford-uuid:de46addf-b6fd-41b8-a02d-ee2c74e529962022-03-27T09:31:12ZMHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humansJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:de46addf-b6fd-41b8-a02d-ee2c74e52996EnglishSymplectic ElementsAmerican Association for the Advancement of Science2020Esposito, ICicconi, PD'Alise, AMBrown, AEsposito, MSwadling, LHolst, PJBassi, MRStornaiuolo, MMori, FVassilev, VLi, WDonnison, TGentile, CTurner, Bvon Delft, ADel Sorbo, MBarra, FContino, AMAbbate, ANovellino, EThomsen, ARChristensen, JPLahm, AGrazioli, FAmmendola, VSiani, LColloca, SKlenerman, PNicosia, ADorrell, LFolgori, ACapone, SBarnes, EPEACHI ConsortiumStrategies to enhance the induction of high magnitude T cell responses through vaccination are urgently needed. Major histocompatibility complex (MHC) class II–associated invariant chain (Ii) plays a critical role in antigen presentation, forming MHC class II peptide complexes for the generation of CD4+ T cell responses. Preclinical studies evaluating the fusion of Ii to antigens encoded in vector delivery systems have shown that this strategy may enhance T cell immune responses to the encoded antigen. We now assess this strategy in humans, using chimpanzee adenovirus 3 and modified vaccinia Ankara vectors encoding human Ii fused to the nonstructural (NS) antigens of hepatitis C virus (HCV) in a heterologous prime/boost regimen. Vaccination was well tolerated and enhanced the peak magnitude, breadth, and proliferative capacity of anti-HCV T cell responses compared to non-Ii vaccines in humans. Very high frequencies of HCV-specific T cells were elicited in humans. Polyfunctional HCV-specific CD8+ and CD4+ responses were induced with up to 30% of CD3+CD8+ cells targeting single HCV epitopes; these were mostly effector memory cells with a high proportion expressing T cell activation and cytolytic markers. No volunteers developed anti-Ii T cell or antibody responses. Using a mouse model and in vitro experiments, we show that Ii fused to NS increases HCV immune responses through enhanced ubiquitination and proteasomal degradation. This strategy could be used to develop more potent HCV vaccines that may contribute to the HCV elimination targets and paves the way for developing class II Ii vaccines against cancer and other infections. |
| spellingShingle | Esposito, I Cicconi, P D'Alise, AM Brown, A Esposito, M Swadling, L Holst, PJ Bassi, MR Stornaiuolo, M Mori, F Vassilev, V Li, W Donnison, T Gentile, C Turner, B von Delft, A Del Sorbo, M Barra, F Contino, AM Abbate, A Novellino, E Thomsen, AR Christensen, JP Lahm, A Grazioli, F Ammendola, V Siani, L Colloca, S Klenerman, P Nicosia, A Dorrell, L Folgori, A Capone, S Barnes, E MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans |
| title | MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans |
| title_full | MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans |
| title_fullStr | MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans |
| title_full_unstemmed | MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans |
| title_short | MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans |
| title_sort | mhc class ii invariant chain adjuvanted viral vectored vaccines enhances t cell responses in humans |
| work_keys_str_mv | AT espositoi mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT cicconip mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT daliseam mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT browna mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT espositom mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT swadlingl mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT holstpj mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT bassimr mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT stornaiuolom mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT morif mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT vassilevv mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT liw mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT donnisont mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT gentilec mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT turnerb mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT vondelfta mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT delsorbom mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT barraf mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT continoam mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT abbatea mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT novellinoe mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT thomsenar mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT christensenjp mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT lahma mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT graziolif mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT ammendolav mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT sianil mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT collocas mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT klenermanp mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT nicosiaa mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT dorrelll mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT folgoria mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT capones mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans AT barnese mhcclassiiinvariantchainadjuvantedviralvectoredvaccinesenhancestcellresponsesinhumans |